Journal
MOLECULAR CANCER
Volume 19, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12943-020-01197-3
Keywords
Epigenetic modification; Cancer; Epi-drugs; Combination strategy; Tumour microenvironment
Categories
Funding
- Research Council of the University of Hong Kong [104004092, 104004460]
- Gaia Family Trust of New Zealand [200007008]
- Research Grants Committee (RGC) of Hong Kong, HKSAR [740608, 766211, 17152116, 17121419]
- Health and Medical Research Fund [15162961, 16172751]
- Preemptive retention fund [202007002]
- Enhanced new staff start-up fund [204610519]
- [200006276]
Ask authors/readers for more resources
Epigenetics is dynamic and heritable modifications to the genome that occur independently of DNA sequence. It requires interactions cohesively with various enzymes and other molecular components. Aberrant epigenetic alterations can lead to inappropriate onset of genetic expressions and promote tumorigenesis. As the epigenetic modifiers are susceptible to extrinsic factors and reversible, they are becoming promising targets in multiple cancer therapies. Recently, various epi-drugs have been developed and implicated in clinical use. The use of epi-drugs alone, or in combination with chemotherapy or immunotherapy, has shown compelling outcomes, including augmentation of anti-tumoral effects, overcoming drug resistance, and activation of host immune response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available